NOVO B — Novo Nordisk A/S Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeLarge CapFalling Star

Annual cashflow statement for Novo Nordisk A/S, fiscal year end - December 31st, DKK millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	47,757	55,525	83,683	100,988	102,434
Depreciation
Non-Cash Items	24,332	35,847	53,373	41,232	24,984
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-23,114	-19,847	-37,561	-40,359	-30,298
Change in Accounts Receivable
Change in Inventories
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Net Change in Other Assets & Liabilities
Other Operating Cash Flow
Cash from Operating Activities	55,000	78,887	108,908	120,968	119,102
Capital Expenditures	-7,385	-14,753	-38,896	-51,309	-90,113
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-24,220	-10,165	-4,996	-77,586	10,955
Acquisition of Business
Sale of Business
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-31,605	-24,918	-43,892	-128,895	-79,158
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-25,493	-51,797	-63,158	8,735	-28,408
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-1,507	1,934	1,739	1,263	10,809